WINDLAS

WINDLAS BIOTECH

Small Cap BSE: 543329 NSE: WINDLAS
₹230.3
-1.4 (-0.6%)
As on 30 September, 2022 | 03:28

Windlas Biotech Share Price

Windlas Biotech Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in WINDLAS BIOTECH

Start SIP

Windlas Biotech Share Returns

  • Over 1 Month 5.76%
  • Over 3 Month 4.59%
  • Over 6 Month 7.34%
  • Over 1 Year -36.16%

Windlas Biotech Key Statistics

P/E Ratio 12.2
PEG Ratio 0.6
Market Cap Cr 502
Price to Book Ratio 1.3
EPS 17.7
Dividend 1.5
Relative Strength Index 48.64
Money Flow Index 69.37
MACD Signal 4.28
Average True Range 9.68

Windlas Biotech Investment Rating

  • Master Rating:
  • Windlas Biotech has an operating revenue of Rs. 474.91 Cr. on a trailing 12-month basis. An annual revenue growth of 10% is good, Pre-tax margin of 10% is healthy, ROE of 9% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 57 which is a POOR score indicating inconsistency in earnings, a RS Rating of 25 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 151 indicates it belongs to a poor industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Windlas Biotech Financials
IndicatorJun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 120122118115111107
Operating Expenses Qtr Cr 1061081051029996
Operating Profit Qtr Cr 141413131211
Depreciation Qtr Cr 333333
Interest Qtr Cr 000000
Tax Qtr Cr 4-13332
Net Profit Qtr Cr 10158876

Windlas Biotech Technicals

EMA & SMA

Current Price
230.3
-1.4 (-0.6%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 233.36
  • 50 Day
  • 228.57
  • 100 Day
  • 229.76
  • 200 Day
  • 240.03
  • 20 Day
  • 235.79
  • 50 Day
  • 225.29
  • 100 Day
  • 223.59
  • 200 Day
  • 239.83

Windlas Biotech Resistance and Support

PIVOT
₹232.62
Resistance
First Resistance 234.74
Second Resistance 237.77
Third Resistance 239.89
RSI 48.64
MFI 69.37
MACD Single Line 4.28
MACD 2.72
Support
First Resistance 229.59
Second Resistance 227.47
Third Resistance 224.44

Windlas Biotech Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 19,900 1,337,479 67.21
Week 33,838 1,881,077 55.59
1 Month 101,281 5,357,740 52.9
6 Month 50,495 2,675,716 52.99

Windlas Biotech Result Highlights

Windlas Biotech Synopsis

NSE-Medical-Ethical Drugs

Windlas Biotech belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 465.93 Cr. and Equity Capital is Rs. 10.90 Cr. for the Year ended 31/03/2022. Windlas Biotech Ltd. is a Public Limited Listed company incorporated on 19/02/2001 and has its registered office in the State of Uttarakhand/Uttaranchal, India. Company’s Corporate Identification Number(CIN) is L74899UR2001PLC033407 and registration number is 033407.
Market Cap 502
Sales 475
Shares in Float 0.87
No of funds 15
Yield 1.52
Book Value 1.27
U/D Vol ratio 1.4
LTDebt / Equity
Alpha -0.16
Beta 0.79

Windlas Biotech

Owner NameJun-22Mar-22Dec-21Sep-21
Promoters 59.95%59.95%59.95%
Mutual Funds 11.9%9.5%9.9%
Insurance Companies 0.08%0.08%0.08%
Foreign Portfolio Investors 3.21%3.4%3.77%
Financial Institutions/ Banks 0.04%0.04%0.04%
Individual Investors 21.57%23.61%22.2%
Others 3.25%3.42%4.06%

Windlas Biotech Management

Name Designation
Mr. Vivek Dhariwal Chairman & Ind.Director
Mr. Hitesh Windlass Managing Director
Mr. Manoj Kumar Windlass Joint Managing Director
Mr. Pawan Kumar Sharma Executive Director
Mr. Ashok Kumar Windlass Whole Time Director
Mrs. Prachi Jain Windlass Non Executive Director
Mr. Srinivasan Venkataraman Ind. Non-Executive Director
Mr. Gaurav Gulati Ind. Non-Executive Director

Windlas Biotech Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Windlas Biotech Corporate Action

Date Purpose Remarks
2022-08-04 Quarterly Results
2022-05-12 Audited Results & Dividend
2022-02-02 Quarterly Results
2021-11-01 Quarterly Results
2021-09-08 Quarterly Results

Windlas Biotech MF Shareholding

Name Amount(cr)
ICICI Prudential Smallcap Fund Growth 4138
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth 2465
UTI Small Cap Fund Regular Growth 2270
Invesco India Smallcap Fund Regular Growth 1345
UTI Healthcare Fund Regular Plan Growth 713

Windlas Biotech FAQs

What is Share Price of Windlas Biotech ?

Windlas Biotech share price is ₹230 As on 30 September, 2022 | 03:14

What is the Market Cap of Windlas Biotech ?

The Market Cap of Windlas Biotech is ₹501.9 Cr As on 30 September, 2022 | 03:14

What is the P/E ratio of Windlas Biotech ?

The P/E ratio of Windlas Biotech is 12.2 As on 30 September, 2022 | 03:14

What is the PB ratio of Windlas Biotech ?

The PB ratio of Windlas Biotech is 1.3 As on 30 September, 2022 | 03:14

Q1FY23